Skip to main content
森萱医药 logo

森萱医药 — Investor Relations & Filings

Ticker · 920946 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 417 across all filing types
Latest filing 2023-02-01 Share Issue/Capital Cha…
Country CN China
Listing Beijing Stock Exchange 920946

About 森萱医药

https://www.senxuan.cn/

Jiangsu Senxuan Pharmaceutical Co., Ltd. specializes in the research, development, and production of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and specialized fine chemicals. The company’s product portfolio includes key intermediates for antiviral medications, such as those used in the treatment of HIV, and anticonvulsant agents like Primidone. Additionally, it produces high-purity chemical solvents including 1,4-dioxane and 1,3-dioxolane for diverse industrial applications. Senxuan Pharmaceutical maintains a focus on advanced chemical synthesis and large-scale manufacturing capabilities, adhering to international quality standards to support the global life sciences and chemical sectors. Its operations are characterized by a commitment to technical innovation and the supply of critical chemical building blocks for complex therapeutic formulations.

Recent filings

Filing Released Lang Actions
股票解除限售公告
Share Issue/Capital Change Classification · 95% confidence The document is a formal announcement from Jiangsu Senxuan Pharmaceutical Co., Ltd. regarding the lifting of trading restrictions on a specific number of shares held by certain directors and senior management. It details the number of shares being unlocked, the shareholders involved, the reasons for the lifting of restrictions, and the updated share capital structure. The document does not contain financial statements, earnings data, or detailed management discussion. It is not a report but an announcement about share capital changes related to restricted shares becoming tradable. This fits the category of Share Issue/Capital Change (SHA), which includes announcements about changes in share capital or share restrictions.
2023-02-01 Chinese
2023年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled as a resolution announcement for the "2023 First Extraordinary General Meeting of Shareholders" of Jiangsu Senxuan Pharmaceutical Co., Ltd. It details the meeting date, attendance, voting results on specific proposals, and legal opinions confirming the validity of the meeting and votes. The content focuses on the announcement of voting results from a shareholders' meeting rather than the meeting materials or the full report. The document length is short (2114 characters), and it primarily reports the official voting outcomes and related procedural details. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2023-01-18 Chinese
江苏汇典律师事务所关于江苏森萱医药股份有限公司2023年第一次临时股东大会之法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the legality of the convening and proceedings of the 2023 first extraordinary general meeting (临时股东大会) of Jiangsu Senxuan Pharmaceutical Co., Ltd. It details the procedures of the meeting, attendance, voting results, and confirms compliance with relevant laws and company articles. It is not a financial report, earnings release, or management discussion, but a legal opinion on the shareholder meeting. This type of document is best classified under Regulatory Filings (RNS) as it is a compliance/legal procedural filing related to corporate governance and shareholder meetings, but not a direct announcement of voting results or AGM materials. The document length is under 5,000 characters and it is a standalone legal opinion letter, not a report publication announcement or proxy solicitation. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2023-01-18 Chinese
持股5%以上股东减持股份结果公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement from Jiangsu Senxuan Pharmaceutical Co., Ltd. regarding the results of a shareholder's reduction in shareholding. It details the shareholder's name, shareholding before and after reduction, the number of shares reduced, the method, period, and price range of the reduction. The document explicitly states it is a 'shareholding reduction result announcement' and includes a statement ensuring the accuracy and completeness of the announcement. There is no financial data, no discussion of company performance, no meeting materials, or legal proceedings. This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels (crossing thresholds). The document length is short and focused solely on shareholding changes, not a report or announcement of a report publication. Therefore, the correct classification is MRQ with high confidence.
2023-01-10 Chinese
简式权益变动报告书
Major Shareholding Notification Classification · 100% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report." It details the reduction in shareholding by an individual shareholder (童贞明) in 江苏森萱医药股份有限公司, including specific dates, share quantities, and percentages. The document includes declarations about the absence of other share transactions and confirms the shareholder's holdings post-change. It is a formal disclosure of a change in major shareholding stakes, referencing regulatory requirements and providing detailed shareholding data. This matches the definition of a Major Shareholding Notification (MRQ), which involves notification of changes in significant share ownership levels crossing thresholds. The document is not an announcement of a report, nor is it a full financial report or management information. Therefore, the correct classification is MRQ with high confidence.
2023-01-03 Chinese
关于预计2023年日常性关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Jiangsu Senxuan Pharmaceutical Co., Ltd. regarding the expected related party transactions for the year 2023. It includes detailed tables of estimated transaction amounts, descriptions of related parties, their financial data, and the approval process by the board and supervisory committee. The document is dated January 3, 2023, and it is a formal announcement of expected related party transactions for the upcoming fiscal year. It does not contain comprehensive financial statements or detailed financial performance data for a fiscal period, nor is it a transcript, audit report, or other specific report type. It is a regulatory announcement about expected related party transactions, which fits best under the category of Regulatory Filings (RNS) as it is a compliance disclosure and does not fit other more specific categories.
2023-01-02 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.